The U.S. compounding pharmacies market size is calculated at USD 6.45 billion in 2025 and is forecasted to reach around USD 10.93 billion by 2034, accelerating at a CAGR of 6.04% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Compounding Pharmacies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Compounding Pharmacies Market, by Pharmacy Type
8.1.1. 503A
8.1.1.1. Market Revenue and Forecast
8.1.2. 503B
8.1.2.1. Market Revenue and Forecast
9.1. U.S. Compounding Pharmacies Market, by Product
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast
9.1.2. Liquid Preparations
9.1.2.1. Market Revenue and Forecast
9.1.3. Topical
9.1.3.1. Market Revenue and Forecast
9.1.4. Rectal
9.1.4.1. Market Revenue and Forecast
9.1.5. Ophthalmic
9.1.5.1. Market Revenue and Forecast
9.1.6. Nasal
9.1.6.1. Market Revenue and Forecast
9.1.7. Otic
9.1.7.1. Market Revenue and Forecast
10.1. U.S. Compounding Pharmacies Market, by Sterility
10.1.1. Sterile
10.1.1.1. Market Revenue and Forecast
10.1.2. Non-Sterile
10.1.2.1. Market Revenue and Forecast
11.1. U.S. Compounding Pharmacies Market, by Compounding Type
11.1.1. Pharmaceutical Ingredient Alteration (PIA)
11.1.1.1. Market Revenue and Forecast
11.1.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
11.1.2.1. Market Revenue and Forecast
11.1.3. Pharmaceutical Dosage Alteration (PDA)
11.1.3.1. Market Revenue and Forecast
11.1.4. Others
12.1. U.S. Compounding Pharmacies Market, by Therapeutic Area
12.1.1. Hormone replacement
12.1.1.1. Market Revenue and Forecast
12.1.2. Pain management
12.1.2.1. Market Revenue and Forecast
12.1.3. Dermatology
12.1.3.1. Market Revenue and Forecast
12.1.4. Pediatrics
12.1.4.1. Market Revenue and Forecast
12.1.5. Urology
12.1.5.1. Market Revenue and Forecast
12.1.6. Others
12.1.6.1. Market Revenue and Forecast
13.1. U.S. Compounding Pharmacies Market, by End-User
13.1.1. Hospitals and Clinics
13.1.1.1. Market Revenue and Forecast
13.1.2. Specialty Clinics
13.1.2.1. Market Revenue and Forecast
13.1.3. Others
13.1.3.1. Market Revenue and Forecast
14.1. U.S.
14.1.1. Market Revenue and Forecast, by Pharmacy Type
14.1.2. Market Revenue and Forecast, by Product
14.1.3. Market Revenue and Forecast, by Sterility
14.1.4. Market Revenue and Forecast, by Compounding Type
14.1.5. Market Revenue and Forecast, by Therapeutic Area
14.1.6. Market Revenue and Forecast, by End-User
15.1. Triangle compounding pharmacy
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Fagron
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. B. Braun melsungen ag
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Fresenius kabi ag
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Pencol Compounding Pharmacy
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. US Compounding Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Avella specialty pharmacy
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Institutional pharmacy solutions, llc
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Pharmedium services llc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Vertisis custom pharmacy
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample